KKR's Global Atlantic Nets $2 Billion From Japan Post Insurance
Japan Post Insurance Co. will invest the funds into a new vehicle that will be managed by KKR's Global Atlantic Financial Group, a New York-based insurer. Japan Post will own a majority stake in the entity, which will invest in all of Global Atlantic's businesses, including annuity products and life insurance.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
15 minutes ago
- Associated Press
SRPT LEGAL ALERT: Lose Money on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT)
NEW YORK, Aug. 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: Investors have until August 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 25-cv-05317. Why Was Sarepta Sued for Securities Fraud? Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta's most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. As alleged, Sarepta repeatedly touted the safety profile of Elevidys and told investors that the benefits of the treatment outweighed its risks. In truth, Elevidys causes fatal acute liver failure in some patients. The Stock Declines as the Truth Is Revealed On March 18, 2025, Sarepta announced that a patient that had been treated with Elevidys died after suffering acute liver failure. On this news, the price of Sarepta stock fell $27.81 per share, or over 27%, from $101.35 per share on March 17, 2025, to $73.54 per share on March 18, 2025. Nevertheless, on the same day, Sarepta assured investors that 'the benefit-risk of ELEVIDYS remains positive.' Next, on June 15, 2025, Sarepta announced that a second patient treated with Elevidys had died from acute liver failure and that it was suspending certain shipments of Elevidys and paused dosing in an ongoing clinical trial of the treatment. On this news, the price of Sarepta stock fell $15.24 per share, or more than 42%, from $36.18 per share on June 13, 2025, to $20.94 per share on June 16, 2025. Finally, on July 17, 2025, Sarepta revealed that a third patient treated with one of Sarepta's investigational treatments related to Elevidys had died from acute liver failure in June 2025. On this news, the price of Sarepta stock fell more than 40% on July 18, 2025. Click here for more information: What Can You Do? If you invested in Sarepta you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212.789.3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.
Associated Press
15 minutes ago
- Associated Press
SJM LEGAL ALERT: Lose Money on Your The J.M. Smucker Co. Investment? Contact BFA Law about its Securities Fraud Investigation (NYSE:SJM)
NEW YORK, Aug. 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into The J.M. Smucker Company (NYSE: SJM) for potential violations of the federal securities laws. If you invested in J.M. Smucker, you are encouraged to obtain additional information by visiting: Why Is J.M. Smucker being Investigated? J.M. Smucker manufactures and markets branded food and beverage products. In November 2023, the company completed an acquisition of Hostess Brands, Inc., a manufacturer and marketer of sweet baked goods brands. The company stated that the Hostess acquisition was 'highly complementary' and that 'underlying trends in snacking and specifically sweet snacking still bode well for the category.' In truth, it appears the company's Sweet Baked Snacks segment, which includes Hostess, significantly deteriorated in the face of declining trends in sweet snacking. The Stock Declines as the Truth Is Revealed On June 10, 2025, J.M. Smucker reported its Q4 2025 financial results and announced that it recognized a $867 million impairment charge related to the goodwill of its Sweet Baked Snacks segment and a $113 million impairment charge related to the Hostess brand trademark driven by the 'continued underperformance of the Sweet Baked Snacks segment.' On this news, the price of J.M. Smucker stock fell $17.44 per share, or more than 18%, from $111.85 per share on June 9, 2025, to $94.41 per share on June 10, 2025. Click here for more information: What Can You Do? If you invested in J.M. Smucker you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212.789.3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.
Business Insider
an hour ago
- Business Insider
3 'Strong Buy' Dividend Stocks with Over 30% Upside, According to Analysts, 8/3/2025
Dividend-paying stocks are a great way to generate passive income and can be considered a safe bet in the current uncertain market situation. Furthermore, these stocks have the potential to generate notable capital gains. To assess these returns, investors can use TipRanks' Dividend Calculator, which helps estimate future income based on investment size. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Leveraging TipRanks' Best Dividend Stocks Screener, we have identified three stocks with Strong Buy ratings from analysts. These stocks also offer a dividend yield above 5%, and analysts see over 30% upside for each in the next 12 months. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio. Here are this week's stocks: Upbound Group (UPBD) – Upbound Group helps people get furniture, electronics, and appliances through lease-to-own plans under brands like Rent-A-Center and Acima. The stock carries a dividend yield of 7.43% and a Smart Score of nine. Interestingly, four out of the five Wall Street analysts covering UPBD stock have rated it a Buy, with their 12-month consensus price target indicating an upside of about 56.03%. Viper Energy (VNOM) – This is a U.S.-based company that owns and buys mineral and royalty interests in oil and natural gas fields, mainly located in the Permian Basin. The stock has a dividend yield of 6.75% and a Smart Score of 'Perfect 10.' In the last three months, all 12 Wall Street analysts covering VNOM stock have rated it a Strong Buy, with their 12-month consensus price target indicating an upside of about 45.49%. Copa Holdings (CPA) – Copa Holdings is a Panama-based airline group that operates flights across the Americas through its subsidiaries Copa Airlines and Wingo. The stock carries a dividend yield of 5.91% and a Smart Score of 'Perfect 10.' In the last three months, all six Wall Street analysts covering CPA stock have rated it a Strong Buy, with their 12-month consensus price target indicating an upside of about 33.80%. What Is TipRanks' Smart Dividend Newsletter? TipRanks Smart Dividends Newsletter delivers a weekly high-quality dividend stock recommendation, backed by detailed analysis and up-to-date market insights. A well-chosen dividend stock can enhance your income investment portfolio and potentially yield long-term returns. For a complete list of dividend stocks and their payout dates, check out the TipRanks Dividend Calendar.
